BDX · News · 20260806N
Regulatory Risk
BECTON DICKINSON & CO · 2026-08-06 · Importance 37 · Surprise 42 · In source text
BD continues to address unresolved FDA Warning Letters concerning its El Paso manufacturing facility and its Dispensing quality management system. The reported regulatory matters could affect operations and create additional liabilities, although no quantified financial exposure or remediation timetable was provided. These issues represent company-specific U.S. regulatory risk rather than standard boilerplate disclosure.
Key facts
- The company continues to address unresolved FDA Warning Letters for its El Paso manufacturing facility and Dispensing quality management system. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | contingent | — | The company continues to address unresolved FDA Warning Letters for its El Paso manufacturing facility and Dispensing quality management… |